10-Q 1 unh-20220331.htm 10-Q unh-20220331
falseQ1000073176612/3100007317662022-01-012022-03-3100007317662022-04-29xbrli:shares00007317662022-03-31iso4217:USD00007317662021-12-31iso4217:USDxbrli:shares00007317662021-01-012021-03-310000731766us-gaap:ProductMember2022-01-012022-03-310000731766us-gaap:ProductMember2021-01-012021-03-310000731766us-gaap:ServiceMember2022-01-012022-03-310000731766us-gaap:ServiceMember2021-01-012021-03-310000731766us-gaap:CommonStockMember2021-12-310000731766us-gaap:AdditionalPaidInCapitalMember2021-12-310000731766us-gaap:RetainedEarningsMember2021-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000731766us-gaap:NoncontrollingInterestMember2021-12-310000731766us-gaap:RetainedEarningsMember2022-01-012022-03-310000731766us-gaap:NoncontrollingInterestMember2022-01-012022-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000731766us-gaap:CommonStockMember2022-01-012022-03-310000731766us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000731766us-gaap:CommonStockMember2022-03-310000731766us-gaap:AdditionalPaidInCapitalMember2022-03-310000731766us-gaap:RetainedEarningsMember2022-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000731766us-gaap:NoncontrollingInterestMember2022-03-310000731766us-gaap:CommonStockMember2020-12-310000731766us-gaap:AdditionalPaidInCapitalMember2020-12-310000731766us-gaap:RetainedEarningsMember2020-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000731766us-gaap:NoncontrollingInterestMember2020-12-3100007317662020-12-310000731766us-gaap:RetainedEarningsMember2021-01-012021-03-310000731766us-gaap:NoncontrollingInterestMember2021-01-012021-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310000731766us-gaap:CommonStockMember2021-01-012021-03-310000731766us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000731766us-gaap:CommonStockMember2021-03-310000731766us-gaap:AdditionalPaidInCapitalMember2021-03-310000731766us-gaap:RetainedEarningsMember2021-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310000731766us-gaap:NoncontrollingInterestMember2021-03-3100007317662021-03-310000731766us-gaap:USTreasuryAndGovernmentMember2022-03-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310000731766us-gaap:CorporateDebtSecuritiesMember2022-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2022-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2022-03-310000731766us-gaap:USTreasuryAndGovernmentMember2021-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000731766us-gaap:CorporateDebtSecuritiesMember2021-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2021-12-310000731766us-gaap:DebtSecuritiesMember2022-03-310000731766us-gaap:DebtSecuritiesMember2021-12-31unh:reportableSegmentsxbrli:pure0000731766us-gaap:FairValueInputsLevel1Member2022-03-310000731766us-gaap:FairValueInputsLevel2Member2022-03-310000731766us-gaap:FairValueInputsLevel3Member2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2022-03-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2022-03-310000731766us-gaap:FairValueInputsLevel1Member2021-12-310000731766us-gaap:FairValueInputsLevel2Member2021-12-310000731766us-gaap:FairValueInputsLevel3Member2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2021-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-03-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-03-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-03-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2022-03-310000731766us-gaap:LongTermDebtMember2022-03-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000731766us-gaap:LongTermDebtMember2021-12-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptuminsightMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766unh:TotalOptumMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766unh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptuminsightMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766unh:TotalOptumMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:CorporateNonSegmentMemberus-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:ProductMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptuminsightMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:ServiceMemberus-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766unh:TotalOptumMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:IntersegmentMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberunh:IntersegmentMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptuminsightMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberunh:IntersegmentMember2022-01-012022-03-310000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2022-01-012022-03-310000731766unh:TotalOptumMemberunh:IntersegmentMember2022-01-012022-03-310000731766us-gaap:CorporateNonSegmentMemberunh:IntersegmentMember2022-01-012022-03-310000731766unh:IntersegmentMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptuminsightMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2022-01-012022-03-310000731766us-gaap:IntersegmentEliminationMember2022-01-012022-03-310000731766unh:TotalOptumMember2022-01-012022-03-310000731766us-gaap:CorporateNonSegmentMember2022-01-012022-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptuminsightMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766unh:TotalOptumMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766unh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptuminsightMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766unh:TotalOptumMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMemberus-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:ProductMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptuminsightMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:ServiceMemberus-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766unh:TotalOptumMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:IntersegmentMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMemberunh:IntersegmentMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptuminsightMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMemberunh:IntersegmentMember2021-01-012021-03-310000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2021-01-012021-03-310000731766unh:TotalOptumMemberunh:IntersegmentMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMemberunh:IntersegmentMember2021-01-012021-03-310000731766unh:IntersegmentMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumhealthMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptuminsightMember2021-01-012021-03-310000731766us-gaap:OperatingSegmentsMemberunh:OptumrxMember2021-01-012021-03-310000731766us-gaap:IntersegmentEliminationMember2021-01-012021-03-310000731766unh:TotalOptumMember2021-01-012021-03-310000731766us-gaap:CorporateNonSegmentMember2021-01-012021-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
Form 10-Q
__________________________________________________________ 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______ TO _______
Commission File Number: 1-10864
__________________________________________________________ 
unh-20220331_g1.jpg
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
Delaware 41-1321939
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
UnitedHealth Group Center 55343
9900 Bren Road East
Minnetonka,
Minnesota
(Address of principal executive offices) (Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
_________________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filerAccelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes No 
As of April 29, 2022, there were 938,171,603 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.



UNITEDHEALTH GROUP
Table of Contents
 
  Page




PART I
ITEM 1.    FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)March 31,
2022
December 31,
2021
Assets
Current assets:
Cash and cash equivalents$25,482 $21,375 
Short-term investments2,914 2,532 
Accounts receivable, net18,871 14,216 
Other current receivables, net11,994 13,866 
Assets under management4,155 4,449 
Prepaid expenses and other current assets5,613 5,320 
Total current assets69,029 61,758 
Long-term investments42,353 43,114 
Property, equipment and capitalized software, net
9,183 8,969 
Goodwill77,548 75,795 
Other intangible assets, net9,918 10,044 
Other assets13,207 12,526 
Total assets$221,238 $212,206 
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable$28,676 $24,483 
Accounts payable and accrued liabilities25,058 24,643 
Short-term borrowings and current maturities of long-term debt6,697 3,620 
Unearned revenues2,675 2,571 
Other current liabilities25,064 22,975 
Total current liabilities88,170 78,292 
Long-term debt, less current maturities40,796 42,383 
Deferred income taxes2,954 3,265 
Other liabilities11,671 11,787 
Total liabilities143,591 135,727 
Commitments and contingencies (Note 5)
Redeemable noncontrolling interests1,519 1,434 
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
  
Common stock, $0.01 par value - 3,000 shares authorized; 939 and 941 issued and outstanding
10 10 
Retained earnings78,782 77,134 
Accumulated other comprehensive loss(6,026)(5,384)
Nonredeemable noncontrolling interests
3,362 3,285 
Total equity76,128 75,045 
Total liabilities, redeemable noncontrolling interests and equity$221,238 $212,206 
1

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
 Three Months Ended March 31,
(in millions, except per share data)20222021
Revenues:
Premiums$64,070 $55,486 
Products9,340 8,340 
Services6,372 5,918 
Investment and other income367 452 
Total revenues80,149 70,196 
Operating costs:
Medical costs52,523 44,904 
Operating costs11,401 10,223 
Cost of products sold8,487 7,572 
Depreciation and amortization788 758 
Total operating costs73,199 63,457 
Earnings from operations6,950 6,739 
Interest expense(433)(397)
Earnings before income taxes6,517 6,342 
Provision for income taxes(1,369)(1,364)
Net earnings5,148 4,978 
Earnings attributable to noncontrolling interests(121)(116)
Net earnings attributable to UnitedHealth Group common shareholders
$5,027 $4,862 
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic
$5.34 $5.14 
Diluted
$5.27 $5.08 
Basic weighted-average number of common shares outstanding941 945 
Dilutive effect of common share equivalents13 12 
Diluted weighted-average number of common shares outstanding
954 957 
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents
2 3 
2

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
 Three Months Ended March 31,
(in millions)20222021
Net earnings$5,148 $4,978 
Other comprehensive loss:
Gross unrealized losses on investment securities during the period(2,023)(764)
Income tax effect465 174 
Total unrealized losses, net of tax(1,558)(590)
Gross reclassification adjustment for net realized gains included in net earnings
(3)(7)
Income tax effect1 2 
Total reclassification adjustment, net of tax
(2)(5)
Total foreign currency translation gains (losses)918 (417)
Other comprehensive loss(642)(1,012)
Comprehensive income4,506 3,966 
Comprehensive income attributable to noncontrolling interests(121)(116)
Comprehensive income attributable to UnitedHealth Group common shareholders
$4,385 $3,850 
3

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive
Income (Loss)
Nonredeemable Noncontrolling InterestsTotal
Equity
Three months ended March 31,
(in millions)
SharesAmountNet Unrealized Gains (losses) on InvestmentsForeign Currency Translation (Losses) Gains
Balance at January 1, 2022941 $10 $ $77,134 $423 $(5,807)$3,285 $75,045 
Net earnings
5,027 88 5,115 
Other comprehensive (loss) income(1,560)918 (642)
Issuances of common stock, and related tax effects
3  333 333 
Share-based compensation
282 282 
Common share repurchases(5) (484)(2,016)(2,500)
Cash dividends paid on common shares ($1.45 per share)
(1,363)(1,363)
Redeemable noncontrolling interests fair value and other adjustments
(131)(131)
Acquisition and other adjustments of nonredeemable noncontrolling interests
91 91 
Distribution to nonredeemable noncontrolling interests
(102)(102)
Balance at March 31, 2022939 $10 $ $78,782 $(1,137)$(4,889)$3,362 $76,128 
Balance at January 1, 2021946 $10 $ $69,295 $1,336 $(5,150)$2,837 $68,328 
Net earnings
4,862 80 4,942 
Other comprehensive loss(595)(417)(1,012)
Issuances of common stock, and related tax effects
3  256 256 
Share-based compensation
242 242 
Common share repurchases(5)  (1,650)(1,650)
Cash dividends paid on common shares ($1.25 per share)
(1,181)(1,181)
Redeemable noncontrolling interests fair value and other adjustments
(498)(106)(604)
Acquisition and other adjustments of nonredeemable noncontrolling interests
66 66 
Distribution to nonredeemable noncontrolling interests
(74)(74)
Balance at March 31, 2021944 $10 $ $71,220 $741 $(5,567)$2,909 $69,313 
4

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Three Months Ended March 31,
(in millions)20222021
Operating activities
Net earnings$5,148 $4,978 
Noncash items:
Depreciation and amortization788 758 
Deferred income taxes161 341 
Share-based compensation299 256 
Other, net17 (55)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable(4,521)(2,895)
Other assets(1,089)(955)
Medical costs payable3,849 2,968 
Accounts payable and other liabilities589 870 
Unearned revenues78 (261)
Cash flows from operating activities5,319 6,005 
Investing activities
Purchases of investments(4,982)(4,612)
Sales of investments1,591 643 
Maturities of investments1,759 2,255 
Cash paid for acquisitions, net of cash assumed(1,231)(1,193)
Purchases of property, equipment and capitalized software(555)(568)
Other, net(255)(232)
Cash flows used for investing activities(3,673)(3,707)
Financing activities
Common share repurchases(2,500)(1,650)
Cash dividends paid(1,363)(1,181)
Proceeds from common stock issuances551 436 
Repayments of long-term debt(1,100)(1,150)
Proceeds from short-term borrowings, net3,148 4,057 
Customer funds administered5,120 2,131 
Other, net(1,552)(1,856)
Cash flows from financing activities2,304 787 
Effect of exchange rate changes on cash and cash equivalents157 (51)
Increase in cash and cash equivalents4,107 3,034 
Cash and cash equivalents, beginning of period21,375 16,921 
Cash and cash equivalents, end of period$25,482 $19,955 
5

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.    Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC (2021 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
6

2.    Investments
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
March 31, 2022
Debt securities - available-for-sale:
U.S. government and agency obligations$3,507 $4 $(140)$3,371 
State and municipal obligations7,022 57 (224)6,855 
Corporate obligations21,669 55 (811)20,913 
U.S. agency mortgage-backed securities6,210 7 (316)5,901 
Non-U.S. agency mortgage-backed securities2,913 2 (112)2,803 
Total debt securities - available-for-sale41,321 125 (1,603)39,843 
Debt securities - held-to-maturity:
U.S. government and agency obligations510 1 (9)502 
State and municipal obligations29   29 
Corporate obligations87   87 
Total debt securities - held-to-maturity626 1 (9)618 
Total debt securities$41,947 $126 $(1,612)$40,461 
December 31, 2021
Debt securities - available-for-sale:
U.S. government and agency obligations$3,206 $23 $(31)$3,198 
State and municipal obligations6,829 297 (20)7,106 
Corporate obligations20,947 372 (145)21,174 
U.S. agency mortgage-backed securities5,868 88 (55)5,901 
Non-U.S. agency mortgage-backed securities2,819 42 (23)2,838 
Total debt securities - available-for-sale39,669 822 (274)40,217 
Debt securities - held-to-maturity:
U.S. government and agency obligations511 2 (2)511 
State and municipal obligations30 2  32 
Corporate obligations100   100 
Total debt securities - held-to-maturity641 4 (2)643 
Total debt securities$40,310 $826 $(276)$40,860 
The Company held $3.5 billion of equity securities as of both March 31, 2022 and December 31, 2021. The Company’s investments in equity securities primarily consist of employee savings plan related investments, other venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.3 billion of equity method investments in operating businesses in the health care sector, as of both March 31, 2022 and December 31, 2021. The allowance for credit losses on held-to-maturity securities at March 31, 2022 and December 31, 2021 was not material.
7

The amortized cost and fair value of debt securities as of March 31, 2022, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost
Fair
Value
Amortized
Cost
Fair
Value
Due in one year or less$2,987 $2,986 $217 $217 
Due after one year through five years12,900 12,608 355 347 
Due after five years through ten years12,055 11,461 29 29 
Due after ten years4,256 4,084 25 25 
U.S. agency mortgage-backed securities6,210 5,901 — — 
Non-U.S. agency mortgage-backed securities2,913 2,803 — — 
Total debt securities$41,321 $39,843 $626 $618 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value
Gross
Unrealized
Losses
Fair
Value
Gross
Unrealized
Losses
Fair
Value
Gross
Unrealized
Losses
March 31, 2022
Debt securities - available-for-sale:
U.S. government and agency obligations
$2,485 $(96)$451 $(44)$2,936 $(140)
State and municipal obligations3,568 (204)218 (20)3,786 (224)
Corporate obligations14,237 (603)2,049 (208)16,286 (811)
U.S. agency mortgage-backed securities4,192 (201)1,225 (115)5,417 (316)
Non-U.S. agency mortgage-backed securities
2,097 (78)348 (34)2,445 (112)
Total debt securities - available-for-sale$26,579 $(1,182)$4,291 $(421)$30,870 $(1,603)
December 31, 2021
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,976 $(18)$249 $(13)$2,225 $(31)
State and municipal obligations1,386 (19)31 (1)$1,417 $(20)
Corporate obligations9,357 (130)376 (15)$9,733 $(145)
U.S. agency mortgage-backed securities3,078 (52)116 (3)$3,194 $(55)
Non-U.S. agency mortgage-backed securities
1,321 (18)114 (5)$1,435 $(23)
Total debt securities - available-for-sale$17,118 $(237)$886 $(37)$18,004 $(274)
The Company’s unrealized losses from debt securities as of March 31, 2022 were generated from approximately 27,000 positions out of a total of 39,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities that impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of March 31, 2022, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2022 and December 31, 2021 was not material.
8

3.    Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and Carrying
Value
March 31, 2022
Cash and cash equivalents$25,382 $100 $ $25,482 
Debt securities - available-for-sale:
U.S. government and agency obligations3,214 157  3,371 
State and municipal obligations 6,855  6,855 
Corporate obligations36 20,670 207 20,913 
U.S. agency mortgage-backed securities 5,901  5,901 
Non-U.S. agency mortgage-backed securities 2,803  2,803 
Total debt securities - available-for-sale3,250 36,386 207 39,843 
Equity securities2,036 20 68 2,124 
Assets under management 1,727 2,333 95 4,155 
Total assets at fair value$32,395 $38,839 $370 $71,604 
Percentage of total assets at fair value45 %54 %%100 %
December 31, 2021
Cash and cash equivalents$21,359 $16 $ $21,375 
Debt securities - available-for-sale:
U.S. government and agency obligations3,017 181  3,198 
State and municipal obligations 7,106  7,106 
Corporate obligations40 20,916 218 21,174 
U.S. agency mortgage-backed securities 5,901  5,901 
Non-U.S. agency mortgage-backed securities 2,838  2,838 
Total debt securities - available-for-sale3,057 36,942 218 40,217 
Equity securities2,090 23 64 2,177 
Assets under management 1,972 2,376 101 4,449 
Total assets at fair value$28,478 $39,357 $383 $68,218 
Percentage of total assets at fair value42 %57 %%100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2022 or 2021.
9

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total Carrying Value
March 31, 2022
Debt securities - held-to-maturity$525 $86 $7 $618 $626 
Long-term debt and other financing obligations$ $46,686 $ $46,686 $43,344 
December 31, 2021
Debt securities - held-to-maturity$534 $102 $7 $643 $641 
Long-term debt and other financing obligations$ $52,583 $ $52,583 $46,003 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during either the three months ended March 31, 2022 or 2021.
4.    Medical Costs Payable
The following table shows the components of the change in medical costs payable for the three months ended March 31:
(in millions)20222021
Medical costs payable, beginning of period$24,483 $21,872 
Acquisitions8 12 
Reported medical costs:
Current year52,813 45,914 
Prior years(290)(1,010)
Total reported medical costs52,523 44,904 
Medical payments:
Payments for current year
(29,589)(25,960)
Payments for prior years(18,749)(15,995)
Total medical payments(48,338)(41,955)
Medical costs payable, end of period$28,676 $24,833 
For the three months ended March 31, 2022, prior years medical cost reserve development included no individual factors that were significant. For the three months ended March 31, 2021, prior years’ medical cost reserve development was primarily driven by lower than expected health system utilization and the uncertainty of care patterns due to the disruption of the health care system caused by COVID-19. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $19.5 billion and $17.1 billion at March 31, 2022 and December 31, 2021, respectively.
5.    Commitments and Contingencies
Pending Acquisitions
As of March 31, 2022, the Company has entered into agreements to acquire companies in the health care sector, most notably Change Healthcare (NASDAQ: CHNG) and LHC Group, Inc. (NASDAQ: LHCG), subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding associated disposition proceeds and the payoff of acquired indebtedness, is approximately $15 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
10

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the DOJ, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper Medicare risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
11

6.    Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
On January 1, 2022, the Company realigned its operating segments to combine UnitedHealthcare Global and UnitedHealthcare Employer & Individual. The realignment had no impact on the Company’s reportable segments.
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations
Consolidated
Three Months Ended March 31, 2022
Revenues - unaffiliated customers:
Premiums$59,937 $4,133 $ $ $ $4,133 $ $64,070 
Products 6 40 9,294  9,340  9,340 
Services2,515 2,558 974 325  3,857  6,372 
Total revenues - unaffiliated customers
62,452 6,697 1,014 9,619  17,330  79,782 
Total revenues - affiliated customers
 9,829 2,138 14,291 (553)25,705 (25,705)